Crying Wolf: Why Negotiating Lower Drug Prices Will Not Harm Pharmaceutical Innovation
More evidence that US drug price curbs are unlikely to be harming pharmaceutical innovation
Read more...More evidence that US drug price curbs are unlikely to be harming pharmaceutical innovation
Read more...An initiative in the Southwestern US demonstrates that health care for the homeless can be financially viable.
Read more...Persistent political and public health failures expose us to pandemics, while vastly underestimating their long-term health effects.
Read more...New investigation reveals unequal access to life-saving meds across Europe thanks to Big Pharma system that favors the rich
Read more...How concept anchoring creates attachment to and supports funding for not-so-hot ideas, such as in Alzheimer’s research.
Read more...The cost-effective investments in healthcare infrastructure disproportionately benefited historically marginalised groups, had long-run benefits, and complemented, rather than substituted, medical innovation.
Read more...How a Biden administration initiative to improve nursing homes’ staffing is floundering due to lax enforcement.
Read more...Many hospitals will have their operations interrupted and/or degraded by climate change. What to do?
Read more...Documenting the role of the AMA in blocking public health care in the US.
Read more...Jonathan Haidt contends that changes in childrearing practices have produced adults who on average are more anxious and fragile
Read more...The US Supreme Court decides it is not cruel to make it illegal for homeless people to sleep.
Read more...A new study finds that revenue-funded healthcare is cost-effective, efficient, and fair, while all health insurance has avoidable excess cost
Read more...Hospitals in the US and UK have been hit hard by cyber attacks, leaving practitioners struggling to offer care.
Read more...Some updates on long Covid make for an indictment of US public health. Not that that should come as a surprise.
Read more...The Biden plan to squeeze the Medicare drug pricing balloon has merely led it to bulge out in a different place.
Read more...